Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 5Urinary Bladder Neoplasms 1Thymus Neoplasms 1Thymoma 1Small Cell Lung Cancer Extensive Stage 1Sarcoma 1Neoplasm Metastasis 1Breast Neoplasms 1

Interventions

Sunitinib 5pembrolizumab 4Paclitaxel 4Carboplatin 4Radiotherapy 3Cyclophosphamide 3Cisplatin 3selinexor 2lenvatinib 2Taxes 2Ramucirumab 2Octreotide 2N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide 2Methylprednisolone 2Erlotinib Hydrochloride 2Chemoradiotherapy 2zimberelimab 1saracatinib 1regorafenib 1epacadostat 1envafolimab 1belinostat 1avelumab 1atezolizumab 1amrubicin 1alovudine 1TP protocol 1Radiofrequency Ablation 1Radiation Dose Hypofractionation 1Prednisone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Thymoma × amrubicin × Clear all
NCT01364727 2019-04-16

A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies

Stanford University

Phase 2 Completed
33 enrolled 11 charts
Thoracic

Thymoma, Thymus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡